LabCorp/$LH

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About LabCorp

Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.

Ticker

$LH
Sector

Primary listing

NYSE

Employees

65,450

LabCorp Metrics

BasicAdvanced
$23B
30.66
$9.07
0.76
$2.88
1.04%

What the Analysts think about LabCorp

Analyst ratings (Buy, Hold, Sell) for LabCorp stock.

Bulls say / Bears say

LabCorp has increased its full-year 2025 adjusted earnings forecast to $16.05–$16.50 per share after surpassing Q2 profit and revenue estimates, driven by strong demand for diagnostic testing.
On Feb. 6, LabCorp projected 2025 revenue of $13.88–$14.05 billion, beating analysts’ average forecast of $13.8 billion, thanks to resilient demand for diagnostic testing among seniors.
LabCorp shares trade at a reasonable 13.9× forward earnings—below their three-year average—and have climbed 3.5% this year amid a sector-wide rise in volumes, supporting an attractive valuation.
LabCorp faces a pending CMS rule on Medicare reimbursement that could reduce payments for lab services under Medicare, which generates about 9% of its revenue.
After several flat years, U.S. medical testing volumes have only recently started growing at about 2% per year, which limits LabCorp’s potential for organic growth.
LabCorp’s biopharma laboratory services business may experience weakness, as spending on contract research from early-stage drug developers has fallen over the past two years.
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2025.

LabCorp Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

LabCorp Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $LH

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

Sept11
LabCorp
Dividend·Payment
$0.72Per share
FAQs